"The Auburn project fits our plans to invest in novel therapeutic approaches that will advance clinical development of new drug compounds. We share the belief that future pharmaceuticals and biologicals will have targeted delivery," explained Russ McLauchlan, CEO of Calvert Holdings Inc. "Our alliance with Auburn University gives us a position in this growing field."
Scheduled to conclude in April 2009, the study's results will be published by Auburn University.
About Calvert Research LLC:
Calvert Research Institute was formed to bridge the gap in the early-stage drug and device development cycle. The group has implemented an innovative model of strategic partnering and can utilize the virtual nature of a consortium of specialized companies and services so that investment communities and start-ups both achieve their goals.
About Auburn University:
For more news about Auburn University, visit http://wireeagle.auburn.edu/. In-depth reporting, including multimedia features and downloadable photographs for media use, can be found at http://www.ocm.auburn.edu/newsmakers/. Auburn University has provided instruction, research, and outreach to benefit the state and nation for more than 150 years, and is among a distinctive group of universities designated as Land, Sea, and Space Grant institutions. Auburn makes a nearly $5 billion economic contribution to the state each year, has more than 250,000 graduates, and provides 130 degree programs to more than 24,000 graduate and under
Copyright©2008 Vocus, Inc.
All rights reserved